Aktis Oncology, Inc.
AKTS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $0 | $0 | $0 |
| - Cash | $37,159 | $29,513 | $128,597 |
| + Debt | $12,010 | $13,402 | $1,775 |
| Enterprise Value | -$25,149 | -$16,111 | -$126,822 |
| Revenue | $1,487 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $1,487 | $0 | $0 |
| % Margin | 100% | – | – |
| EBITDA | -$50,475 | -$33,598 | -$19,319 |
| % Margin | -3,394.4% | – | – |
| Net Income | -$43,980 | -$28,641 | -$17,929 |
| % Margin | -2,957.6% | – | – |
| EPS Diluted | 0 | 0 | 0 |
| % Growth | – | – | – |
| Operating Cash Flow | $14,762 | -$30,004 | -$18,125 |
| Capital Expenditures | -$2,862 | -$3,764 | -$2,307 |
| Free Cash Flow | $11,900 | -$33,768 | -$20,432 |